2025-09-09 - Analysis Report
Okay, here's a report analyzing Merck & Co Inc (MRK) based on the provided data.

**Merck & Co Inc (MRK) Stock Analysis**

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops and markets a wide range of healthcare products.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return Disparity:** MRK's cumulative return is -7.64% compared to VOO's 101.31%.
*   **Divergence:** The divergence between MRK and VOO is significant.
    *   Max: 23.1
    *   Min: -111.9
    *   Current: -108.9
    *   Relative Divergence: 2.2
*   **Analysis:** MRK has significantly underperformed the S&P 500. The relative divergence suggests that MRK's performance is near the lowest end of its historical range compared to the S&P 500.
*   **Alpha/Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha    | Beta   | Cap(B) |
| ---------- | ------- | ------ | -------- | ------ | ------ |
| 2015-2017  | 5.0%    | 58.2%  | -24.0%   | -0.0   | 133.1  |
| 2016-2018  | 43.0%   | 66.4%  | 25.0%    | -0.1   | 180.8  |
| 2017-2019  | 40.0%   | 66.4%  | 11.0%    | 0.3    | 215.2  |
| 2018-2020  | 20.0%   | 66.4%  | 0.0%     | 0.3    | 193.5  |
| 2019-2021  | -1.0%   | 65.6%  | -50.0%   | 0.3    | 190.0  |
| 2020-2022  | 13.0%   | 69.5%  | 11.0%    | 0.3    | 275.1  |
| 2021-2023  | 31.0%   | 69.5%  | 13.0%    | 0.3    | 270.3  |
| 2022-2024  | -7.0%   | 69.5%  | -33.0%   | 0.2    | 246.7  |
| 2023-2025  | -60.0%  | 71.5%  | -113.0%  | 0.5    | 210.0  |

*   **Analysis:** The Alpha/Beta analysis reveals that in recent years (2019-2025), MRK has struggled to generate excess returns (negative Alpha) and exhibits a positive Beta, indicating a tendency to move in the same direction as the market, but with less intensity. The negative CAGR and high MDD (Maximum Drawdown) in the most recent period (2023-2025) are concerning.

**2. Recent Price Action**

*   **Current Price:** 84.71
*   **Last Market Data:** Price: 84.09, Previous Close: 84.71, Change: -0.73
*   **Moving Averages:**
    *   5-day MA: 84.34
    *   20-day MA: 83.86
    *   60-day MA: 82.06
*   **Analysis:** The stock price is currently trading above its 5-day, 20-day, and 60-day moving averages, suggesting a short-term uptrend. The recent price change (-0.73) indicates a slight downward movement in the most recent trading session.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 52.37 (Neutral)
*   **PPO:** -0.1239 (Neutral)
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **Recent (20-day) Relative Divergence Change:** 2.2 (+) - Short-term increase
*   **Expected Return:** -589.8%
*   **Analysis:**
    *   The MRI indicates a low-risk market environment for MRK.
    *   The RSI is neutral, suggesting neither overbought nor oversold conditions.
    *   The PPO is slightly negative, indicating a potential for further decline.
    *   The hybrid signal suggests a cautious buying strategy, allocating 80% of available cash.
    *   The recent increase in relative divergence suggests a short-term upward trend.
    *   The significantly negative expected return (-589.8%) is a major cause for concern, indicating potential underperformance compared to the S&P 500 over a long-term investment horizon.
    *   The recent price change of -0.73 reflects a small recent down movement

**4. Recent News & Significant Events**

*   **[2025-09-08] Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch:** This article suggests that a competitor's drug has failed to outperform Merck's, which could be a positive signal for MRK.
*   **[2025-09-08] Merck (MRK) Gains Breakthrough Therapy Designation For Lung Cancer Drug:**  This is a positive development, indicating that the FDA recognizes the potential of Merck's lung cancer drug.
*   **[2025-09-08] Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy:**  Indirect News
*   **[2025-09-08] J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?** Indirect News
*   **[2025-09-08] Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences:**  Further indication of potential positive news for Merck's Keytruda.
*   **[2025-09-08] Top Dividend Stocks To Consider In September 2025:** This suggests MRK may be considered a good dividend stock, appealing to income-seeking investors.
*   **Analysis:** The news is a mixed bag. The Breakthrough Therapy Designation is positive, but the overall market context and competitive landscape need to be considered carefully.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.96 (~Buy)
*   **Opinions:** 24
*   **Target Price (avg/high/low):** 102.33 / 141.00 / 82.00
*   **Recent Rating Changes:** Not provided.
*   **Analysis:** Analyst consensus is positive, with a "Buy" rating and an average target price significantly higher than the current price. However, the wide range between the high and low target prices indicates uncertainty among analysts. The lack of recent rating changes makes it difficult to assess current sentiment shifts.

**5. Recent Earnings Analysis**

| 날짜        | EPS  | 매출      |
| ----------- | ---- | --------- |
| 2025-08-05  | 1.76 | 15.81 B$  |
| 2025-05-02  | 2.01 | 15.53 B$  |
| 2024-11-06  | 1.25 | 16.66 B$  |
| 2024-08-05  | 2.15 | 16.11 B$  |
| 2025-08-05  | 2.15 | 16.11 B$  |

*   **Analysis:**
    *   The EPS shows some volatility over the last few quarters.
    *   Revenue has also fluctuated but remains relatively stable.
    *   There is a duplicate entry for 2025-08-05, which could indicate an error in the data.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| ------------ | ---------- | ------------- |
| 2025-06-30   | $15.81B   | 77.50%        |
| 2025-03-31   | $15.53B   | 77.98%        |
| 2024-12-31   | $15.62B   | 75.50%        |
| 2024-09-30   | $16.66B   | 75.51%        |
| 2024-06-30   | $16.11B   | 76.76%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE     |
| ------------ | ---------- | ------- |
| 2025-06-30   | $48.99B   | 9.04%   |
| 2025-03-31   | $48.34B   | 10.51%  |
| 2024-12-31   | $46.31B   | 8.08%   |
| 2024-09-30   | $44.50B   | 7.09%   |
| 2024-06-30   | $43.58B   | 12.52%  |

*   **Analysis:**
    *   Revenue has been relatively stable over the past year.
    *   Profit margins are consistently high, indicating strong profitability.
    *   Equity has been increasing steadily.
    *   ROE (Return on Equity) has fluctuated, suggesting changes in how efficiently Merck is using shareholder equity to generate profits.

**7. Overall Assessment**

*   **Underperformance:** MRK has significantly underperformed the S&P 500, with a large negative divergence.
*   **Technical Signals:** Mixed signals from technical indicators, with a short-term uptrend indicated by moving averages, but a negative expected return.
*   **Analyst Opinion:**  Analysts are generally positive on the stock, but target price ranges are wide.
*   **Financials:**  Strong profitability (high profit margins) and increasing equity are positives, but ROE has been volatile.
*   **News:**  Recent news is mixed, with positive developments regarding a lung cancer drug but overall mixed information regarding the sector.

**Conclusion:**

MRK's recent performance has been weak compared to the broader market. While analysts are generally optimistic and the company exhibits strong profitability, the negative expected return and mixed technical signals warrant caution. Investors should carefully consider the risks and potential rewards before investing in MRK. The recent Breakthrough Therapy Designation for the lung cancer drug and the failure of a competitor's drug are positive signs, but the overall picture requires further investigation.
